13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001643354
Total reported value
$20.9M
$20.9M
25 檔
143.3%
At the close of Q3 2024, Lion Point Capital, LP disclosed equity holdings valued at approximately $20.9M, spread across 25 reported holdings.
In Q3 2024, Lion Point Capital, LP adopted a defensive or profit-taking posture, trimming 8 positions and completely liquidating 6 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including IWM, INSM, GERN) accounted for 143.3% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 40.58% | — | — | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 8.49% | — | -25.78% | |
| 3 | GERN | Geron CORP | Stock-Other | 6.37% | -1.61% | — | |
| 4 | ARDX | Ardelyx Inc | Stock-Other | 5.68% | -1.47% | -56.81% | |
| 5 | MIST | Milestone Pharmaceuticals In | Stock-Other | 5.60% | -0.57% | -29.32% | |
| 6 | BHVN | Biohaven Ltd. | Stock-Other | 3.94% | +1.07% | — | |
| 7 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 3.91% | — | — | |
| 8 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 3.42% | — | -41.35% | |
| 9 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.78% | -0.44% | — | |
| 10 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 2.72% | — | -67.19% | |
| 11 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 2.39% | +1.65% | +26.47% | |
| 12 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 2.13% | -0.34% | — | |
| 13 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.98% | -1.27% | -28.92% | |
| 14 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 1.87% | — | -22.42% | |
| 15 | ✓ | Stock-Other | 1.83% | — | +132.69% | ||
| 16 | RGNX | Regenxbio Inc | Stock-Other | 1.35% | +0.19% | +59.31% | |
| 17 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.34% | -1.50% | — | |
| 18 | IRON | Disc Medicine Inc | Stock-Other | 0.84% | -0.27% | — | |
| 19 | BNTC | Benitec Biopharma Inc | Stock-Other | 0.80% | +0.02% | — | |
| 20 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.73% | -0.08% | — | |
| 21 | MCRB1EUR | Seres Therapeutics Inc | Stock-Other | 0.72% | — | — | |
| 22 | 4NX1 | Lumos Pharma Inc | Stock-Other | 0.34% | — | -56.40% | |
| 23 | MSFT | Microsoft CORP | Stock-Tech | 0.10% | — | — | |
| 24 | SPRU | Spruce Power Holding Corporation | Stock-Other | 0.08% | — | — | |
| 25 | GOOG | Alphabet Inc-cl C | Stock-Comm Services | 0.04% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IWM | Ishares Russell 2000 ETF | +10.1% | — | Unchanged |
| 2 | BHVN | Biohaven Ltd. | +3.9% | NEW | New buy |
| 3 | GERN | Geron CORP | +1.5% | — | Unchanged |
| 4 | MIRM | Mirum Pharmaceuticals Inc | +1.1% | — | Unchanged |
| 5 | IRON | Disc Medicine Inc | +0.8% | NEW | New buy |
| 6 | BNTC | Benitec Biopharma Inc | +0.8% | NEW | New buy |
| 7 | ARQT | Arcutis Biotherapeutics Inc | +0.7% | NEW | New buy |
| 8 | ✓ | +0.6% | +132.69% | Add | |
| 9 | RGNX | Regenxbio Inc | +0.6% | +59.31% | Add |
| 10 | BBIO | Bridgebio Pharma Inc | +0.5% | — | Unchanged |
| 11 | FENC | Fennec Pharmaceuticals Inc | +0.5% | +26.47% | Add |
| 12 | MLYS | Mineralys Therapeutics Inc | +0.5% | — | Unchanged |
| 13 | MCRB1EUR | Seres Therapeutics Inc | +0.3% | — | Unchanged |
| 14 | JSPR | Jasper Therapeutics Inc | 0% | — | Unchanged |
| 15 | MSFT | Microsoft CORP | 0% | — | Unchanged |
| 16 | SPRU | Spruce Power Holding Corporation | 0% | — | Unchanged |
| 17 | GOOG | Alphabet Inc-cl C | 0% | — | Unchanged |
| 18 | MIST | Milestone Pharmaceuticals In | 0% | -29.32% | Trim |
| 19 | 4NX1 | Lumos Pharma Inc | 0% | -56.40% | Trim |
| 20 | ✓ | Burgerfi International Inc | -0.1% | EXIT | Sold out |
| 21 | BATL | Battalion Oil CORP | -0.1% | EXIT | Sold out |
| 22 | INSM | Insmed Inc | -0.1% | -25.78% | Trim |
| 23 | KNSA | Kiniksa Pharmaceuticals International, plc | -0.1% | -41.35% | Trim |
| 24 | ✓ | Avadel Pharmaceuticals PLC ADR | -0.2% | -22.42% | Trim |
| 25 | SNDX | Syndax Pharmaceuticals Inc | -0.5% | -28.92% | Trim |
| 26 | 0LS | Burgerfi International Inc | -1% | EXIT | Sold out |
| 27 | ✓ | Enphys Acquisition CORP | -1.6% | EXIT | Sold out |
| 28 | MRNS* | Marinus Pharmaceuticals Inc | -1.8% | -67.19% | Trim |
| 29 | NBIX | Neurocrine Biosciences Inc | -2.1% | EXIT | Sold out |
| 30 | ARDX | Ardelyx Inc | -5.9% | -56.81% | Trim |
| 31 | XBI | Ss Spdr S&p Biotech ETF | -8.5% | EXIT | Sold out |
According to official SEC Form 13F filings, Lion Point Capital, LP reported a total U.S. public equity portfolio value of $20.9M across 25 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
BHVN
市值: $1.8M
Top Position Liquidated / Trimmed
XBI
前期市值: $4.6M
During Q3 2024, Lion Point Capital, LP's top holdings by market value included IWM (40.6%)、INSM (8.5%)、GERN (6.4%). The largest single position, IWM, represented 40.6% of total portfolio value.
In Q3 2024, Lion Point Capital, LP made 21 total portfolio adjustments, initiating 4 new buys, adding to 3 positions, trimming 8 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.